CFRXQ

0.00010.00%
SC

Steven C. Gilman

Vice Chairman

Dr. Steven C. Gilman, also known as Steve, Ph.D., is Scientific Advisor of Spero Therapeutics, Inc. Dr. Gilman has been Vice Chairman of ContraFect Corporation since April 2, 2019. Dr. Gilman served as Chief Executive Officer and President of ContraFect Corporation from July 21, 2016 to April 2, 2019 and as its Executive Chairman from May 20, 2015 to April 2, 2019. Dr. Gilman served as an Interim Chief Executive Officer of ContraFect Corporation from March 21, 2016 to July 21, 2016. Dr. Gilman served as the Chief Scientific Officer at Cubist Pharmaceuticals Inc. since February 2008 and served as its Executive Vice President of Research & Development since September 2010 until January 2015. He has drug research and development experience. He served as a Senior Vice President of Discovery & Non Clinical Development at Cubist Pharmaceuticals Inc. from February 2008 to September 2010. Dr. Gilman was with Cubist Pharmaceuticals from 2008 to January 2015, when Cubist was acquired by Merck. He served as the Chairman of the Board of ActivBiotics, Inc. from March 2004 to October 2007 and also as its Chief Executive Officer from March 2004 to February 2008 and President from March 2004 to May 1, 2007. He served as the Chief Executive Officer and President of ActivBiotics Canada Inc., a subsidiary of ActivBiotics, Inc. While at ActivBiotics, he led the transition of the ActivBiotics from early research/academic stage to focus on advanced product development and commercialization. He served as Vice President and General Manager of Inflammation Franchise of Millennium Pharmaceuticals, Inc from October 2000 to March 2004, where he held a number of senior leadership roles including Vice President and General Manager of the Inflammation Franchise. He served as Group Director of Pfizer Global Research and Development, where he was responsible for drug discovery of novel antibacterial agents as well as several other therapeutic areas. He has also held scientific, business and academic appointments at Wyeth, Cytogen Corporation, Temple Medical School and Connecticut College. He was responsible for pharmaceutical research units at Sterling Winthrop and Wyeth Laboratories in areas including chronic inflammatory diseases, transplant rejection, autoimmune diseases and bacterial infections. He served as Director of Momenta Pharmaceuticals Inc. since June 22, 2016 until October 01, 2020. He has been an Independent Director of SCYNEXIS, Inc. since February 25, 2015 and Vericel Corporation since January 2015. He was an Independent Director of Keryx Biopharmaceuticals Inc. since March 2016 until December 12, 2018. He has been a Director of ContraFect Corporation since May 20, 2015. He serves on the Biotechnology Advisory Board of Penn State University. He serves on director of the Massachusetts Biotechnology Council and Nextcea, Inc. He serves as a Director of the Northeastern University Drug Discovery Advisory Board. He serves as an Independent Director of Akebia Therapeutics, Inc. since December 12, 2018. He served as a Director of Inhibikase Therapeutics, Inc. from May 2011 to January 8, 2016. He served as a Director of ActivBiotics, Inc. since March 2004. He is an author of over 60 publications and 7 US patents. He completed a Post-Doctoral Research Fellowship in the Department of Immunopathology at the Scripps Clinic and Research Foundation. Dr. Gilman received his B.A. degree in microbiology from Miami University (Ohio) and his M.S. and Ph.D. degrees in Microbiology from Pennsylvania State University.

Positions